Choi, Ki Young Jeon, Eun Jung Yoon, Hong Yeol Lee, Beom Suk Na, Jin Hee Min, Kyung Hyun Kim, Sang Yoon Myung, Seung-Jae Lee, Seulki Chen, Xiaoyuan Kwon, Ick Chan Choi, Kuiwon Jeong, Seo Young Kim, Kwangmeyung Park, Jae Hyung 2024-01-20T14:03:33Z 2024-01-20T14:03:33Z 2021-09-04 2012-09 0142-9612 https://pubs.kist.re.kr/handle/201004/128944 Colon cancer is the second leading cause of cancer-related death in the United States. The considerable mortality from colon cancer is due to metastasis to other organs, mainly the liver. In the management of colon cancer, early detection and targeted therapy are crucial. In this study, we aimed to establish a versatile theranostic system for early tumor detection and targeted tumor therapy by using poly(ethylene glycol)-conjugated hyaluronic acid nanoparticles (P-HA-NPs) which can selectively accumulate in tumor tissue. For the diagnostic application, a near-infrared fluorescence (NIRF) imaging dye (Cy 5.5) was chemically conjugated onto the HA backbone of P-HA-NPs. After intravenous injection of Cy5.5-P-HA-NPs into the tumor-bearing mice, small-sized colon tumors as well as liver-implanted colon tumors were effectively visualized using the NIRF imaging technique. For targeted therapy, we physically encapsulated the anticancer drug, irinotecan (IRT), into the hydrophobic cores of P-HA-NPs. Owing to their notable tumor targeting capability, IRT-P-HA-NPs exhibited an excellent antitumor activity while showing a reduction in undesirable systemic toxicity. Importantly, we demonstrated the theranostic application using Cy5.5-P-HA-NPs and IRT-P-HA-NPs in orthotopic colon cancer models. Following the systemic administration of Cy5.5-P-HA-NPs, neoplasia was clearly visualized, and the tumor growth was effectively suppressed by intravenous injection of IRT-P-HA-NPs. It should be emphasized that the therapeutic responses could be simultaneously monitored by Cy5.5-P-HA-NPs. Our results suggest that P-HA-NPs can be used as a versatile theranostic system for the early detection, targeted therapy, and therapeutic monitoring of colon cancer. (C) 2012 Elsevier Ltd. All rights reserved. English ELSEVIER SCI LTD COLORECTAL-CANCER 1ST-LINE TREATMENT FLUOROURACIL LEUCOVORIN CARCINOMA AGENT CD44 Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer Article 10.1016/j.biomaterials.2012.05.029 1 BIOMATERIALS, v.33, no.26, pp.6186 - 6193 BIOMATERIALS 33 26 6186 6193 scie scopus 000306720400022 2-s2.0-84862880702 Engineering, Biomedical Materials Science, Biomaterials Engineering Materials Science Article COLORECTAL-CANCER 1ST-LINE TREATMENT FLUOROURACIL LEUCOVORIN CARCINOMA AGENT CD44 Irinotecan Colon cancer Tumor targeting Hyaluronic acid Nanoparticle Theranostics